TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

IMMUDEX

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

IMMUDEX

ST13

US500000088019409

Classe

1, 5, 42

Pedido

88019409

Registro

6031798

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

55

Atualização mais recente

06/07/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 42

Data de depósito

28/06/2018

Data de registro

14/04/2020

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

06/07/2026

Última transação

06/07/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

702

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use, Foreign priority

Código do desenho

4

Tipo de titular

16

Localização do titular

Virum, DK

Examinador

PHILLIPS, WENDELL SHARMAN

Localização atual

Historical data usage

Titulares e representantes

Titulares

I. A. (pessoa física)
I. A. (pessoa física)

Representantes

Julie A. Greenberg Fishman Stewart PLLC

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Chemicals used in diagnostics, industry and science, other than for medical or veterinary purposes; diagnostic and research reagents for scientific and diagnostic purposes other than medical or veterinary diagnostic purposes; diagnostic test materials for scientific and diagnostic purposes other than medical or veterinary diagnostic purposes; diagnostic kits for scientific and diagnostic purposes other than medical or veterinary diagnostic purposes consisting primarily of MHC multimer reagents, monoclonal antibodies, reagents, diagnostic agents, control reagents,[ DNA/RNA oligo's and ] DNA/RNA oligo conjugated reagents; assays for research and diagnostic purposes other than medical or veterinary diagnostic purposes; biochemical reagents used for non-medical purposes; chemical preparations for analysis for research purposes related to vaccines and immunotherapy, cancer vaccines, borrelia vaccines, TB-vaccines, HIV-vaccines, CMV-vaccines and other vaccines, and for analysis for research purposes of [T-cell lymphoma,] T-cell infiltration of solid tumors and tissue, and for analysis for research purposes of infectious diseases, autoimmunity and for use in connection with toxicological studies and research in relation to transplantation, immune monitoring, vaccines and T-cell monitoring; chemical reagents other than for medicinal and veterinary purposes

Classe 5

[ Preparations for pharmaceutical purposes for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; preparations for medical purposes for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; chemical-pharmaceutical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases;] diagnostic preparations for medical purposes; reagents for medical and veterinary purposes; vaccines; chemical preparations for analysis for medical diagnostic purposes in relation to vaccines, immunotherapeutics and cellular therapies, including cancer vaccines and immunotherapeutics, borrelia vaccines, TB-vaccines, HIV-vaccines and CMV-vaccines, T-cell therapies, and for use in connection with cancer therapy and other medical therapies, for analysis and treatment o [T-cell lymphoma,] T-cell infiltration of solid tumors and tissue, and for infectious diseases, and for use in connection with medical procedures and diagnosis, namely transplantation, immune monitoring, and vaccines and T-cell monitoring

Classe 42

Scientific research services; diagnostic services related to scientific research; basic research and clinical research in relation to medicine and vaccine development; research and development in the field of diagnostic preparations

Publicações

Histórico de despachos e eventos da marca no USPTO.

55 publicações encontradas

PRAN

POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED

06/07/2026

NA85

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

06/07/2026

C15A

REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

06/07/2026

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

29/06/2026

E815

TEAS SECTION 8 & 15 RECEIVED

31/03/2026

REM1

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

14/04/2025

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

09/12/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

09/12/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

09/12/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

12/11/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/11/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/11/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

14/04/2023

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

14/04/2023

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

14/04/2023

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

14/04/2023

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

14/04/2023

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

14/04/2023

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

16/12/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

16/12/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

16/12/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

16/12/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

16/12/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

12/07/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

12/07/2021

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

12/07/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

12/07/2021

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

12/07/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

12/07/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

14/04/2020

DP1B

1(B) BASIS DELETED; PROCEED TO REGISTRATION

11/03/2020

IUCN

NOTICE OF ALLOWANCE CANCELLED

11/03/2020

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

10/03/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

14/01/2020

PUBO

PUBLISHED FOR OPPOSITION

14/01/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

25/12/2019

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/12/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

29/11/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

29/11/2019

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

22/11/2019

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

24/05/2019

GNFR

FINAL REFUSAL E-MAILED

24/05/2019

CNFR

FINAL REFUSAL WRITTEN

24/05/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/05/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/05/2019

ALIE

ASSIGNED TO LIE

06/05/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

25/04/2019

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

25/01/2019

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

25/01/2019

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

26/10/2018

GNRT

NON-FINAL ACTION E-MAILED

26/10/2018

CNRT

NON-FINAL ACTION WRITTEN

26/10/2018

DOCK

ASSIGNED TO EXAMINER

18/10/2018

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

03/07/2018

NWAP

NEW APPLICATION ENTERED

02/07/2018

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace IMMUDEX ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.